Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 2, 2011, Pages 163-172

  Jwala, Jwala ^a   Boddu, Sai H S ^b   Shah, Sujay ^a   Sirimulla, Suman ^c   Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; DEXTRO VALINE DEXTRO VALINE ACICLOVIR; DEXTRO VALINE LEVO VALINE ACICLOVIR; LEVO VALINE DEXTRO VALINE ACICLOVIR; LEVO VALINE LEVO VALINE ACICLOVIR; NANOPARTICLE; PEPTIDE TRANSPORTER 1; POLYGLACTIN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DISPERSION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; EPITHELIUM CELL; HEAT SENSITIVITY; HERPES SIMPLEX KERATITIS; IN VITRO STUDY; MALE; MOLECULAR DOCKING; NONHUMAN; PARTICLE SIZE; SUSTAINED RELEASE PREPARATION;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DIPEPTIDES; EYE; LACTIC ACID; MALE; NANOPARTICLES; POLYGLYCOLIC ACID; PRODRUGS; RABBITS; SOLUBILITY; STEREOISOMERISM;

EID: 79955026932     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0188     Document Type: Article

References (37)

1. Toma, H.S., et al. Ocular HSV-1 latency, reactivation and recurrent disease. Semin. Ophthalmol. 23:249-273, 2008. (Pubitemid 351918598)
2. Shimomura, Y. [Herpes simplex virus latency, reactivation, and a new antiviral therapy for herpetic keratitis]. Nippon Ganka Gakkai Zasshi 112:247-264; discussion 265, 2008.
3. Liesegang, T.J. Ocular herpes simplex infection: pathogene-sis and current therapy. Mayo Clin. Proc 63:1092-1105,1988.
4. Wander, A.H. Herpes simplex and recurrent corneal disease. Int. Ophthalmol. Clin. 24:27-38, 1984.
5. Turner, J., et al. Influence of increased age on the development of herpes stromal keratitis. Exp. Gerontol. 38:1205-1212, 2003. (Pubitemid 37324432)
6. Jabs, D.A. Acyclovir for recurrent herpes simplex virus oc-ular disease. N. Engl. J. Med. 339:340-341, 1998. (Pubitemid 28366425)
7. Falcon, M.G. Herpes simplex virus infections of the eye and their management with acyclovir. J. Antimicrob. Chemother. 12 Suppl B:39-43, 1983. (Pubitemid 14227997)
8. Hughes, P.M., and Mitra, A.K. Effect of acylation on the ocular disposition of acyclovir. II: corneal permeability and anti-HSV 1 activity of 2'-esters in rabbit epithelial keratitis. J. Ocul. Pharmacol. 9:299-309, 1993. (Pubitemid 24006862)
9. Anand, B.S., and Mitra, AK. Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide trans-porter on the rabbit cornea. Pharm. Res. 19:1194-1202, 2002. (Pubitemid 34985004)
10. Anand, B., Nashed, Y., and Mitra, A. Novel dipeptide pro-drugs of acyclovir for ocular herpes infections: bioreversion, antiviral activity and transport across rabbit cornea. Curr. Eye. Res. 26:151-163, 2003. (Pubitemid 36829642)
11. Gulsen, D., and Chauhan, A. Ophthalmic drug delivery through contact lenses. Invest. Ophthalmol. Vis. Sci. 45:2342-2347, 2004. (Pubitemid 38902607)
12. Boddu, S.H., et al. Novel nanoparticulate gel formulations of steroids for the treatment of macular edema. J. Ocul. Phar-macol. Ther. 26:37-48, 2010.
13. de Campos, A.M., et al. Chitosan nanoparticles as new oc-ular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm. Res. 21:803-810, 2004. (Pubitemid 39011304)
14. Nashed, Y.E., and Mitra, A.K. Synthesis and characterization of novel dipeptide ester prodrugs of acyclovir. Spectrochim. Acta. A Mol. Biomol. Spectrosc 59:2033-2039, 2003.
15. Talluri, R.S., et al. Synthesis, metabolism and cellular per-meability of enzymatically stable dipeptide prodrugs of acyclovir. Int. J. Pharm. 361:118-124, 2008.
16. Agarwal, S., et al. Peptide prodrugs: improved oral ab-sorption of lopinavir, a HIV protease inhibitor. Int. J. Pharm. 359:7-14, 2008.
17. Katragadda, S., et al. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evalua-tion of their utility in treating ocular HSV infections. Int. J. Pharm. 359:15-24, 2008.
18. Tak, R.V., et al. Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line. J. Pharm. Sci. 90:1505-1515, 2001. (Pubitemid 32979745)
19. www.uniprot.org/uniprot/P36836.
20. Zhang, Y. I-TASSER: fully automated protein structure prediction in CASP8. Proteins 77 Suppl 9:100-113, 2009.
21. Roy, A., Kucukural A., and Zhang, Y. I-TASSER: a unified platform for automated protein structure and function pre-diction. Nat. Protoc 5:725-738, 2010.
22. Zhang, Y. I-TASSER server for protein 3D structure predic-tion. BMC Bioinform. 9:40, 2008
23. Prime, v. 2.1, and L. Schrödinger. New York, 2010.
24. Jorgensen, W., and Tirado-Rives, J. The OPLS force field for proteins. Energy minimizations for crystals of cyclic pep-tides and crambin. J. Am. Chem. Soc 110:1657-1666, 1988.
25. Maestro, version 9.0. New York: L. Schrödinger; 2010.
26. Ligprep, version 2.3. New York: L. Schrödinger; 2010.
27. Glide, version 5.5. New York: L. Schrödinger; 2010.
28. Meredith, D., and Price, R.A. Molecular modeling of PepT1\towards a structure. J. Membr. Biol. 213:79-88, 2006.
29. Glide 5.5. User Manual. New York: L. Schrödinger; 2010.
30. Friesner, RA., et al. Glide: a new approach for rapid, accu-rate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47:1739-1749, 2004. (Pubitemid 38380917)
31. Katragadda, S., Talluri, RS., and Mitra, A.K. Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea. J. Ocul. Pharmacol. Ther. 22:110-120,2006. (Pubitemid 43742947)
32. Vandervoort, J., and Ludwig, A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int. J. Pharm. 238:77-92, 2002. (Pubitemid 34457877)
33. Wagstaff, A.J., Faulds, D., and Goa, K.L. Aciclovir. A re-appraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:153-205, 1994. (Pubitemid 24032382)
34. Duvvuri, S., Janoria, K.G., and Mitra, A.K. Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J. Control Release 108:282-293, 2005. (Pubitemid 41608661)
35. Cortesi, R, and Esposito, E. Acyclovir delivery systems. Expert Opin. Drug Deliv. 5:1217-1230, 2008.
36. Anand, B.S., et al. In vivo ocular pharmacokinetics of acy-clovir dipeptide ester prodrugs by microdialysis in rabbits. Mol. Pharm. 3:431-440, 2006. (Pubitemid 44351926)
37. Kaur, I.P., and Kanwar, M. Ocular preparations: the for-mulation approach. Drug Dev. Ind. Pharm. 28:473-493, 2002.